HADLIMA

PeakmAb

adalimumab-bwwd

Samsung Bioepis
BLAINJECTIONINJECTABLE
Approved
Jul 2019
Lifecycle
Peak
Competitive Pressure
30/100

Mechanism of Action

Tumor Necrosis Factor Receptor Blocking Activity

Pharmacologic Class:

Tumor Necrosis Factor Blocker

Company
Samsung Bioepis
Samsung Bioepis
Korea - Incheon
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers